InspireMD Inc NSPR.OQ NSPR.O is expected to show a fall in quarterly revenue when it reports results on May 9 for the period ending March 31 2025
The Tel Aviv-yafo Israel-based company is expected to report a 4.0% decrease in revenue to $1.45 million from $1.51 million a year ago, according to the mean estimate from 2 analysts, based on LSEG data.
LSEG's mean analyst estimate for InspireMD Inc is for a loss of 20 cents per share.
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for InspireMD Inc is $4.75, above its last closing price of $2.52.
This summary was machine generated May 7 at 13:00 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)